Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00116844
Status:
COMPLETED
Last Update Posted:
2018-02-12
First Post:
2005-06-30
Brief Title:
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 HSV-2 Seropositive Subjects VALTREX Tablet is a Trademark of GlaxoSmithKline Group of Companies
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Eligible subjects will be randomized to receive VALTREX tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None